Department of Biochemistry and Molecular Biology, The School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
Curr Drug Targets. 2010 Jun;11(6):716-32. doi: 10.2174/138945010791170897.
Current therapeutic options for patients with progressive thyroid cancer are relatively ineffective. There is a clear need to develop new alternatives for the management of this malignancy. As the knowledge of thyroid cancer biology advances, a large number of genetic events, molecular abnormalities, alterations of signaling pathways have been identified in the development and progression of thyroid neoplasms, and the potential exists to develop compounds targeted to treat thyroid cancers that do not respond to traditional therapy. In this review we described the recent development in thyroid carcinogenesis where the potential and novel intervention may exist. The discussion of thyroid carcinogenesis was integrated with exploitation of anti-thyroid agents that are currently either in clinical trials or in preclinical development for thyroid cancer.
目前,进展期甲状腺癌患者的治疗选择相对有限。显然需要开发新的方法来治疗这种恶性肿瘤。随着对甲状腺癌生物学认识的不断深入,在甲状腺肿瘤的发生和发展过程中已经发现了大量的基因事件、分子异常和信号通路改变,因此有可能开发出针对传统治疗无效的甲状腺癌的靶向化合物。在这篇综述中,我们描述了甲状腺癌发生发展的最新进展,其中可能存在潜在的新干预措施。在讨论甲状腺癌发生发展的同时,还探讨了目前正在临床试验或临床前开发阶段的抗甲状腺药物。